ORGS vs. AYTU, TNXP, GLYC, TLPH, NRSN, NERV, GLTO, TRAW, KALA, and VBIV
Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Aytu BioPharma (AYTU), Tonix Pharmaceuticals (TNXP), GlycoMimetics (GLYC), Talphera (TLPH), NeuroSense Therapeutics (NRSN), Minerva Neurosciences (NERV), Galecto (GLTO), Traws Pharma (TRAW), KALA BIO (KALA), and VBI Vaccines (VBIV). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.
Aytu BioPharma has higher revenue and earnings than Orgenesis.
Aytu BioPharma has a consensus target price of $5.00, suggesting a potential upside of 56.25%. Given Aytu BioPharma's higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than Orgenesis.
In the previous week, Orgenesis had 2 more articles in the media than Aytu BioPharma. MarketBeat recorded 5 mentions for Orgenesis and 3 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 1.66 beat Orgenesis' score of 0.26 indicating that Aytu BioPharma is being referred to more favorably in the news media.
Aytu BioPharma received 254 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 67.11% of users gave Aytu BioPharma an outperform vote.
Orgenesis has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.23, suggesting that its share price is 223% less volatile than the S&P 500.
Aytu BioPharma has a net margin of -14.60% compared to Orgenesis' net margin of -1,343.97%. Aytu BioPharma's return on equity of -31.31% beat Orgenesis' return on equity.
22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by insiders. Comparatively, 2.8% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Aytu BioPharma beats Orgenesis on 10 of the 15 factors compared between the two stocks.
Get Orgenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orgenesis Competitors List
Related Companies and Tools
